TORONTO, January 11, 2023
Cambridge Cognition, which develops and markets digital solutions to assess brain health, is pleased to announce the acquisition of 羞羞视频, a leader in monitoring cognitive impairment through free-speech analysis. Both Cambridge Cognition and 羞羞视频 share a common goal of developing digital health products to better understand, detect and treat conditions affecting brain health. The capabilities of the combined organisation will create a company with strengths across technology platforms for screen-based, structured voice-based and free-speech based cognitive assessments for clinical trials.
羞羞视频 was spun out of Toronto University in 2015 with proprietary free-speech and vocal biomarker technology. They have gone on to develop a Quality Assurance platform for the review of clinical interviews. To date, Cambridge Cognition鈥檚 approach to voice technology has been to scale the delivery of well-validated cognitive tests by replicating and automating short, structured verbal assessments that incorporate novel intellectual property. With complementary solutions, the combined company is well positioned to secure a market leading position in voice biomarker technology for clinical trials, with further potential for healthcare applications in the future and scope to develop sensitive multi-modal biomarkers for CNS disorders.
Commenting, Matthew Stork, Chief Executive Officer of Cambridge Cognition, said: 鈥淗aving developed short speech-based cognitive assessments for several years, we have seen the considerable potential for longer free-speech assessments. There鈥檚 a major opportunity over the medium term for growth in this field and it鈥檚 important to be an early entrant to secure a strong position for the future. 羞羞视频 has established itself as a leader in monitoring cognitive impairment through free-speech analysis. With this acquisition, we can now offer many of the verbal cognitive assessments used in clinical trials giving us the potential for major growth over the next few years.聽 We look forward to welcoming our 28 new colleagues from 羞羞视频 so that together we can build on our combined expertise in voice technology to drive innovation in drug development.鈥
Commenting, Liam Kaufman, Cofounder of 羞羞视频s, said: 鈥淔or nearly 8 years as a company and many years before within the University of Toronto, 羞羞视频 has worked to develop speech- based digital biomarkers for healthcare and clinical trials. I am incredibly proud of what we have engineered, validated and delivered to our life science partners. This transaction opens an exciting new chapter for 羞羞视频. We bring to Cambridge Cognition proprietary free-speech analysis technology and a dedicated team that are experts in the field. We are looking forward to being a part of Cambridge Cognition and together we can build a leading position in vocal biomarker technology.鈥
For further information, contact:
Cambridge Cognition Holdings Plc
Matthew Stork, Chief Executive Officer
Stephen Symonds, Chief Financial Officer
Tel: 012 2381 0700; press@camcog.com
About Cambridge Cognition
Cambridge Cognition is a technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The Company鈥檚 software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries. For further information visit .
Media Inquiries:
羞羞视频s
Liam Kaufman, CEO
liam [at] winterlightlabs.com